Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections.

@article{Swenson2005ViruslikePE,
  title={Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections.},
  author={Dana L. Swenson and Kelly Lyn Warfield and Diane L. Negley and Alan L. Schmaljohn and M Javad Aman and Sina Bavari},
  journal={Vaccine},
  year={2005},
  volume={23 23},
  pages={
          3033-42
        }
}
A safe and effective pan-filovirus vaccine is highly desirable since the filoviruses Ebola virus (EBOV) and Marburg virus (MARV) cause highly lethal disease typified by unimpeded viral replication and severe hemorrhagic fever. Previously, we showed that expression of the homologous glycoprotein (GP) and matrix protein VP40 from a single filovirus, either EBOV or MARV, resulted in formation of wild-type virus-like particles (VLPs) in mammalian cells. When used as a vaccine, the wild-type VLPs… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 61 CITATIONS, ESTIMATED 54% COVERAGE

Ebola virus vaccines: an overview of current approaches.

  • Expert review of vaccines
  • 2014
VIEW 8 EXCERPTS
HIGHLY INFLUENCED

Status and challenges of filovirus vaccines.

VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2005
2018

CITATION STATISTICS

  • 5 Highly Influenced Citations

References

Publications referenced by this paper.
SHOWING 1-10 OF 37 REFERENCES

Ebola virus-like particles protect from lethal Ebola virus infection.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2003

In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2003